Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study

Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study

Abstract NEPA is the only fixed combination antiemetic, comprised of an NK1RA (netupitant) and a 5‐HT3RA (palonosetron). In the first head‐to‐head trial to compare NK1RA‐containing regimens, a single oral dose of NEPA was non‐inferior to a 3‐day aprepitant/granisetron (APR/GRAN) regimen for the prim...

Full description

Bibliographic Details
Main Authors: Jianhua Chang, Gongyan Chen, Dong Wang, Guihua Wang, Shun Lu, Jifeng Feng, Wei Li, Ping Li, Corinna Lanzarotti, Salvatore Chessari, Li Zhang
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Cancer Medicine
Subjects:
antiemetic
aprepitant
CINV
NEPA
palonosetron
Online Access:https://doi.org/10.1002/cam4.3123

Internet

https://doi.org/10.1002/cam4.3123

Similar Items